Myelomonocytic Leukemia
📧 Sign up to get email alerts when something new happens for Myelomonocytic Leukemia.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2022-09-23FDA Approved: VIDAZA — Supplemental Application (Celgene Corporation)
The FDA approved a supplemental application for Vidaza (azacitidine) submitted by Celgene Corporation.
-
CLINICAL_TRIALS trial_result · 2022-09-22Clinical Trial Update: Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML) [Phase 3]
This Phase 3 trial compares pevonedistat plus azacitidine versus azacitidine alone as first-line therapy for higher-risk myelodysplastic syn…
-
CLINICAL_TRIALS trial_result · 2022-08-01Clinical Trial Update: Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Total Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome [Phase 2]
Phase 2 clinical trial evaluating a combined regimen including iodine-131 monoclonal antibody BC8, fludarabine phosphate, total body irradia…
-
FDA approval · 2022-03-24FDA Approved: INQOVI — Supplemental Application (Taiho Pharmaceutical Co., Ltd.)
The FDA approved a supplemental application for INQOVI, the oral fixed-dose combination of cedazuridine and decitabine from Taiho Pharmaceut…
-
CLINICAL_TRIALS trial_result · 2022-03-15Clinical Trial Update: Azacytidine + HAG Regimen vs. Azacytidine for Elderly Patients With Newly Diagnosed Myeloid Malignancy [Phase 4]
Clinical trial comparing azacitidine plus HAG regimen versus azacitidine in elderly patients with newly diagnosed myeloid malignancies; phas…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2022-01-04Clinical Trial Update: Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate [NA]
Clinical trial update of imatinib mesylate for various myeloproliferative and related neoplasms including CMML, CML, polycythemia vera, hype…
-
CLINICAL_TRIALS trial_result · 2021-10-04Clinical Trial Update: Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia [Phase 2]
Phase 2 trial update on a targeted therapy for relapsed/refractory acute lymphoblastic leukemia and acute myeloid leukemia; trial status ter…
-
CLINICAL_TRIALS trial_result · 2021-07-08Clinical Trial Update: Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia [Phase 3]
Phase 3 clinical trial evaluating lenalidomide with or without epoetin alfa for myelodysplastic syndrome and associated anemia, with results…
-
CLINICAL_TRIALS trial_result · 2021-06-16Clinical Trial Update: Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine [Phase 1, Phase 2]
Phase II extension study of oral rigosertib in combination with azacitidine in myelodysplastic syndrome and related conditions has completed…
-
CLINICAL_TRIALS trial_result · 2021-06-11Clinical Trial Update: Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation [Phase 2]
Phase 2 trial update on Total Body Irradiation with or without Total Lymphoid Irradiation and Anti-Thymocyte Globulin in non-myeloablative h…
-
CLINICAL_TRIALS trial_result · 2021-05-19Clinical Trial Update: Leukemia SPORE Phase II DAC Study for R/R and Elderly Acute AML and MDS [Phase 2]
Phase II trial update for DAC in relapsed/refractory and elderly patients with acute myeloid leukemia and myelodysplastic syndrome.
-
CLINICAL_TRIALS trial_result · 2021-04-20Clinical Trial Update: A Study of Eltrombopag in Patients With CMML and Thrombocytopenia [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating eltrombopag in CMML patients with thrombocytopenia has completed.
-
CLINICAL_TRIALS trial_result · 2021-03-05Clinical Trial Update: A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In Untreated MDS, AML and CMML Patients [Phase 1]
A Phase 1 trial evaluating the combination of glasdegib (PF-04449913) with azacitidine in untreated myelodysplastic syndrome, acute myeloid …
-
CLINICAL_TRIALS trial_result · 2021-02-25Clinical Trial Update: Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms [Phase 1, Phase 2]
Phase 1b/2 trial assessing APR-246 plus azacitidine in TP53-mutant myeloid neoplasms completed with posted results.
-
FDA approval · 2020-07-13FDA Approved: AZACITIDINE — Supplemental Application (BluePoint Laboratories)
FDA approved a supplemental application for azacitidine submitted by BluePoint Laboratories, representing a modification to the existing NDA…
-
FDA approval · 2020-07-07FDA Approved: INQOVI — Original Application (Taiho Pharmaceutical Co., Ltd.)
FDA approved INQOVI (cedazuridine and decitabine) from Taiho Pharmaceutical Co., Ltd. under an original NDA (NDA 212576) for adults with mye…
-
CLINICAL_TRIALS trial_result · 2020-06-30Clinical Trial Update: Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine [Phase 3]
Phase 3 trial updating the efficacy and safety of intravenous rigosertib in myelodysplastic syndrome patients with excess blasts who progres…
-
CLINICAL_TRIALS trial_result · 2020-06-23Clinical Trial Update: A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML). [Phase 1, Phase 2]
Phase Ib/IIb open-label study evaluating oral panobinostat with 5-azacitidine in adults with myelodysplastic syndromes, chronic myelomonocyt…
-
FDA approval · 2020-06-08FDA Approved: AZACITIDINE — Original Application (Hikma Pharmaceuticals USA Inc.)
FDA approved Hikma Pharmaceuticals USA Inc.'s generic azacitidine (AZACITIDINE) through an Original Application (ANDA 209337). This adds a g…
-
CLINICAL_TRIALS trial_result · 2020-05-28Clinical Trial Update: Azacitidine, Lenalidomide and DLI as Salvage Therapy for MDS, CMML and sAML Relapsing After Allo-HSCT [Phase 2]
Phase 2 clinical trial evaluating azacitidine, lenalidomide, and donor lymphocyte infusion as salvage therapy for relapsed diseases after al…
-
CLINICAL_TRIALS trial_result · 2020-03-12Clinical Trial Update: A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib [Phase 1, Phase 2]
Completed Phase 1/2 trial evaluating safety and efficacy of ruxolitinib in myelomonocytic leukemia.
-
CLINICAL_TRIALS trial_result · 2020-01-21Clinical Trial Update: Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT [Phase 1]
Phase 1 trial exploring a calcineurin inhibitor-free graft-versus-host disease prevention regimen after related haploidentical peripheral bl…
-
CLINICAL_TRIALS trial_result · 2020-01-07Clinical Trial Update: Erlotinib Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia [Phase 2]
Phase 2 clinical trial evaluating erlotinib hydrochloride in relapsed or refractory acute myeloid leukemia has completed with posted results…
-
CLINICAL_TRIALS trial_result · 2019-09-06Clinical Trial Update: WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome [Phase 2]
Phase 2 trial evaluating the WEE1 inhibitor AZD1775 with or without cytarabine in advanced acute myeloid leukemia or myelodysplastic syndrom…
-
CLINICAL_TRIALS trial_result · 2019-06-13Clinical Trial Update: Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML) [Phase 2]
Phase 2 study evaluating sotatercept for anemia in patients with low- or intermediate-1 risk myelodysplastic syndromes and non-proliferative…